Definium Therapeutics Stifel 2026 Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Thanks, everybody, for joining. Thanks especially to Max for joining. Happy to be here with Dan Karlin, Chief Medical Officer of Definium Therapeutics. I am sure folks know the story well, but super topical time for Definium, so maybe I will just have Dan briefly set the stage on what is coming up from you guys from an update perspective, and then we will dig into it. Thanks again. Good to see you.
Yeah. It is great to be here. Thanks for coming, everybody. Dan Karlin, Chief Medical Officer of Definium Therapeutics. I am a psychiatrist by training. Still practice a tiny little bit of psychotherapy, and I am also trained in addictions and clinical informatics. I have been with the company for just about six years, working alongside Rob Barrow, who is our CEO, to build now to 194 people as of Monday, and we are adding like 10 a week, which is a bit alarming in certain ways, but really exciting to be at this point. We are developing DT120, which is our lab code for our LSD formulation, which is a pharmaceutically optimized version of LSD in a Zydis oral dissolving tablet formulation.
We have now read out three phase III studies with DT120, two in GAD and one in MDD, and we did that just about 10 weeks over the summer, which was made for not the most relaxing summer in most of our lives, but extraordinarily reassuring about the strength of the drug. On the back of those three positive phase III readouts, we will be submitting an NDA to FDA in the first half of next year, and we intend to find a path to submit for both GAD and MDD. So that is where we are at. We also, just recently, as of yesterday, announced that our second molecule in clinical development, which is DT402, which is our R, the right enantiomer of MDMA, which we are developing as a daily drug for autism spectrum disorder.
We announced that our EOSE study, early signals of efficacy, had read out as positive, and that will enable us to continue the development of that drug.
That is one of my two favorite enantiomers of MDMA.
Well, you know. God, with you up here, I have to hit you with the nerdiest joke possible.
It is really actually kind of an interesting thing, right? Stereospecificity in neurobiology is wild, and the two enantiomers of MDMA behave really differently.
Yeah we picked this one for a reason, but the level of differentiation between the enantiomers is something that we could nerd out about for a while.
Okay. All right. We'll definitely save some time to do that. Obviously, the update around the NDA filing is around the corner. You guys have talked about this base case of filing the two together, and I think there is some regulatory precedent and context for sort of a second indication having one study, but these are coming together. Most of the time, people with MDD have two pivotals. What's sort of the current thought process or confidence level that this is a realistic base case still?
Yeah. I mean, we've been engaged with FDA through this entire process, and the evidence for that, like our fingerprints are all over the psychedelics guidance. We made choices, we brought FDA along on those choices, they gave us some direction that they wanted to see, and all of that ended up being more or less enshrined in what is now the sort of standard for conducting these studies. From the outset, we made sure to bring them along on this journey. How these filings look exactly is still under discussion, right? The main goal with the filings is we come out of the far side with both labels, and FDA's got a lot on their plate.
They are more understaffed than they've been in quite a long time because of things that happened at the beginning of the current administration, but they are really enthusiastic, a weird kind of framework, but they're enthusiastic to regulate these drugs and to do it in a way that has exactly the same objective we do, which is get drug to patients in a way that's maximally safe and efficacious. They see that shared responsibility as very much an opportunity for them, and I think that's a change from, say, five years ago when it felt much more like they saw their objective as protecting people from these drugs.
Yeah, to slow this pace down and make sure nothing bad happens.
Yeah, can we make sure nothing bad happens?
Yeah. There's still, there's certainly, none of us want to see bad things, but the framework in psychiatry is so often sort of focus on the potential risk then maybe there's some benefit.
It's like, can you imagine if you're having a conversation with an oncology company and someone's like, "Well, someone might be hurt by that drug." It's like, well, these are diseases that truly hurt people, right? That kill people. The recognition of that, both at a regulatory level and a societal level, you see this in the current political process with the conversation around veterans and their mental illness. A Veteran a day dying of mental illness, right? This is not something that has really penetrated the sort of cultural consciousness in this way before.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
